BEIJING, May 15 (Xinhua) — The White House is preparing an executive order requiring some essential drugs to be produced in the United States, U.S. financial media CNBC reported, citing people familiar with the matter. One of the sources said the order could be announced as early as Friday local time, with a 90-day review period.
The Trump administration is working extensively on products from various sectors that are seen as national security issues, including drugs, medical supplies, semiconductors and defense equipment, the sources said.
Janet Woodcock, director of the U.S. Food and Drug Administration, said in testimony to Congress last October that about 72 per cent of pharmaceutical ingredients that supply U.S. medicines are overseas.
Peter Navarro, Mr. Trump’s trade adviser, has previously said he wants an executive order to reduce America’s dependence on foreign drugs.
According to a draft of the order obtained by Bloomberg, it would require any federal contracts for such products to be awarded to U.S. companies and would require production to be distributed to multiple companies to ensure price competition. The drugs and equipment covered by the Order include any products used to respond to public health emergencies or biohazard attacks. Under the executive order, the list of so-called “essential drugs” will be determined at a later date.